ACIP Updates: Key Recommendations from June 2024 Meetings
The Advisory Committee on Immunization Practices (ACIP) recently convened to discuss adn vote on crucial updates to vaccination recommendations. These discussions cover a range of preventative health measures, impacting individuals of all ages. Here’s a thorough overview of the key takeaways from the June 2024 meetings, designed to help you stay informed about the latest guidance.
Influenza Vaccines
ACIP addressed the composition of influenza vaccines for the upcoming season, focusing on optimal protection against circulating strains. Current data indicates the predominant strains are an H1N1, H3N2, and a B/Victoria lineage virus.
Key Recommendations:
Routine influenza vaccination is now recommended for everyone 6 months and older, following a unanimous (11-0) ACIP vote.
for solid organ transplant recipients aged 18-64 taking immunosuppressive medications, both high-dose (HD-IIV3) and adjuvanted (aIIV3) inactivated influenza vaccines are acceptable options.
These options are considered equivalent to other age-appropriate inactivated or recombinant influenza vaccines.
Pneumococcal Vaccines
ACIP reviewed recommendations for PCV21, a newer pneumococcal conjugate vaccine, for adults aged 19 and older. This vaccine offers expanded protection against pneumococcal infections.
Important Updates:
PCV21 covers 81% of pneumococcal serotypes commonly found in adults.
It provides healthcare providers with another valuable tool to safeguard adult patients.
ACIP unanimously (11-0) recommended PCV21 as an option for adults who currently have a proposal to receive a pneumococcal conjugate vaccine.
Meningococcal Vaccines
Discussions surrounding the adolescent meningococcal vaccine schedule are ongoing. ACIP is working to optimize protection, particularly for higher-risk age groups.
What’s Next:
The committee is considering recent epidemiological data, the duration of vaccine-induced protection, and the availability of a new pentavalent (ABCWY) vaccine from GSK.
Further discussion will continue at the October 2024 ACIP meeting.
RSV Vaccines – Maternal/Pediatric
Real-world data on the safety and effectiveness of recently launched RSV vaccines and immunizations were a central focus. These interventions aim to protect infants from severe respiratory syncytial virus (RSV) infections.
Current Guidance:
the CDC continues to reccommend RSV immunizations to protect all babies from severe RSV. Nirsevimab, a long-acting monoclonal antibody, has proven effective in reducing RSV-associated emergency department visits and hospitalizations. You can find more information about Nirsevimab